 |
|
|
| |
Results From the Phase 2 PEARL-I Study: Interferon-free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection
|
| |
| |
Reported by Jules Levin
Presented at the American College of Gastroenterology-79th Annual Scientific Meeting, October 17-22, 2014, Philadelphia, Pennsylvania, United States
Christophe Hezode1, Patrick Marcellin2, Stanislas Pol3, Tarek Hassanein4, Katarzyna Fleischer-Stepniewska5, Tianli Wang6, Sandra S Lovell6, Tami Pilot-Mati as6, Regis A Vilchez6
1Assistance Publique Hopitaux de Paris, Paris, France; 2Hôpital Beaujon Inserm Crb3-U 773-Service Hepatologie, Clichy, France; 3Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France; 4Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 5EMC Instytut Medyczny Spolka Akcyjna, Wroclaw, Poland;
6AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
